TrumpRx.gov Explained: Why FDA and Customs Are Cracking Down on Drug Imports
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
TrumpRx.gov Explained: Why FDA and Customs Are Cracking Down on Drug Imports
-
ナレーター：
-
著者：
Episode Summary: In this episode of *FDA Imports: Cross-Border Compliance* Benjamin England delves into the significance of TrumpRX.gov in the context of drug pricing policy and pharmaceutical importation. Exploring the complexities of pharmaceutical pricing disparities between the US and Europe, Ben sheds light on the regulatory changes initiated by the Trump administration to facilitate the importation of pharmaceuticals, offering a potential solution to high drug costs for American consumers.
Key Timestamps: 00:00 – Introduction 02:30 – TrumpRX.gov: A Game-Changer in Pharmaceutical Pricing 06:45 – The Implications of Temporary Programs on Industry Players 10:15 – Enforcement Approaches to Gray Market Rx Drugs 14:50 – Mitigating Risks in Pharmaceutical Importation 18:25 – The Complexities of Regulatory Scrutiny and Sourcing Patterns
About the Show: *FDA Imports: Cross-Border Compliance* provides expert insights into cross-border compliance issues related to FDA regulations and international trade. Led by Attorney Benjamin England, the show navigates the intricate landscape of FDA oversight, regulatory compliance, and importation challenges faced by businesses worldwide.